Morning Briefing
Summaries of health policy coverage from major news organizations
Public Isn't Taking AMR Seriously; Protein That Causes Clotting After Covid Vaccine Identified
CIDRAP: What's In A Name? Surveys Highlight Public's Problems With Term 'Antimicrobial Resistance'
A new study suggests that the terms "antimicrobial resistance" and "AMR" aren't the best for communicating the dangers of antibiotic-resistant infections to the public, and that a more memorable and alarming term may be needed to raise public awareness. (Dall, 10/30)
ScienceDaily: Protein Interaction Causing Rare But Deadly Vaccine-Related Clotting Found
A mechanism that led some patients to experience cases of deadly clotting following some types of Covid-19 vaccination has been identified in new research. (University of Birmingham, 10/30)
Reuters: Pfizer RSV Vaccine Lags GSK’s As Head-To-Head Competition Underway
Pfizer, which dominated COVID vaccine sales, now finds itself looking up at GSK, whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer. GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data seen by Reuters. (Erman, 10/30)
CIDRAP: Unapproved Stem-Cell Therapies Marketed To People With Long COVID
New research has identified 38 direct-to-consumer businesses marketing stem-cell treatments and exosome therapies for COVID-19 infections and, especially, long COVID, despite lacking approval by US Food and Drug Administration and other regulatory body in the United States. Descriptions of the businesses and an analysis of their marketing strategies are published in Stem Cell Reports. (Soucheray, 10/30)
Reuters: Sarepta's Muscular Dystrophy Therapy Fails To Meet Main Goal In Late-Stage Trial
Sarepta Therapeutics gene therapy to treat Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disorder, failed to meet the main goal of a late-stage trial when tested in patients between 4 and 7 years, the company said on Monday. (10/30)
Reuters: Bayer Ordered To Pay $175 Million In Latest Roundup Cancer Trial
A Philadelphia jury on Friday found Bayer AG liable in a case brought by a retired restaurant owner who claimed his cancer was due to exposure to the company's Roundup weed killer, and ordered Bayer to pay him $175 million in damages, the man's lawyers said. The verdict, for retired restaurant owner Ernest Caranci, includes $25 million in compensatory damages and $150 million in punitive damages. (Pierson, 10/27)
